Aptamers link Archemix, Elan | Chemical & Engineering News
Volume 84 Issue 30 | p. 17 | Concentrates
Issue Date: July 24, 2006

Aptamers link Archemix, Elan

Department: Business

Archemix and Elan have joined forces to discover and develop aptamers, single-stranded nucleic acids whose binding behavior is similar to that of antibodies, for the treatment of autoimmune disease. Archemix snares a $7 million up-front payment from Elan and could receive more than $350 million in milestones and royalties. The companies will target IL-23, a cytokine that is a mediator in chronic autoimmune inflammatory diseases such as multiple sclerosis, Crohn's disease, psoriasis, and rheumatoid arthritis.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment